Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 4:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–35 of 35 matching trials from the live ClinicalTrials.gov search.

Conditions: Kidney Cancer
Interventions: Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250); Biological
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 16 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia
Interventions: Fludarabine, Fractionated total body irradiation, Busulfan, Cyclophosphamide, Single dose total body irradiation, Melphalan, Granulocyte-colony stimulating factor, Stem cell transplant, Azacitidine; Drug · Radiation · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hematologic Malignancy, Myeloid Malignancy
Interventions: Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG), Cyclosporine, Cyclophosphamide, Fludarabine, Methotrexate, Total Body Irradiation (radiation treatment), Bone marrow infusion, Busulfan, Thiotepa; Drug · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 12 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Prostate Cancer
Interventions: Leuprolide, Degarelix or Relugolix, Stereotactic body radiation therapy/radiosurgery (SBRT); Drug · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL), Myelodysplastic Syndromes (MDS)
Interventions: Personalized rATG (P-rATG), Hyper fractionated total body irradiation, Thiotepa, Cyclophosphamide, GCSF, Busulfan, Melphalan, Fludarabine; Other · Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 4 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Hematologic Neoplasms
Interventions: AMD3100, Leukopheresis, Stem cell transplant; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
Interventions: filgrastim, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, total-body irradiation; Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 55 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2019
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Seattle, Washington

Conditions: Hematologic Malignancies
Interventions: Haploidentical Transplant, Fludarabine, Busulfan, Total Body Irradiation, Cyclophosphamide; Procedure · Drug · Radiation
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 10 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Scleroderma, Systemic, Sclerosis, Autoimmune Disease
Interventions: mHSCT, cyclophosphamide; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 69 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 15
States / cities: Duarte, California • Los Angeles, California • Lexington, Kentucky + 10 more

Conditions: Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
Interventions: Total Body Irradiation (TBI), Thiotepa, Cyclophosphamide, Busulfan, Melphalan, Fludarabine; Radiation · Drug
Lead sponsor: Guenther Koehne; Other
Eligibility: 18 Years to 74 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lymphoma, Non-Hodgkin, Leukemia, Blood and Marrow Transplant (BMT), Lymphomas: Non-Hodgkin
Interventions: ablative allogeneic hematopoietic cell transplantation; Procedure
Lead sponsor: Stanford University; Other
Eligibility: Up to 50 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2009
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.